Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of BMS-779788 in healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BMS-779788 or Placebo (Arm 1) | Active Comparator |
| |
| BMS-779788 or Placebo (Arm 2) | Active Comparator |
| |
| BMS-779788 or Placebo (Arm 3) | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-779788 | Drug | Oral Solution, Oral, 1 mg, Once daily, 7 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Safety assessment, including medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests | 8 times within 27 days of the first dose |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (Target gene expression of BMS-779788 in whole blood and adipose tissue and corresponding serum markers) | After each dose panel |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Heidelberg | Victoria | 3084 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40695410 | Derived | Richartz J, Yam SC, Zhan N, Schepers M, Tiane A, Mulder MT, Wens I, Vanmierlo T. Liver X receptors: A therapeutic target in demyelinating disorders. Pharmacol Res. 2025 Sep;219:107861. doi: 10.1016/j.phrs.2025.107861. Epub 2025 Jul 20. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000596177 | 2-(2-(1-(2-chlorophenyl)-1-methylethyl)-1-(3'-(methylsulfonyl)-4-biphenylyl)-1H-imidazol-4-yl)-2-propanol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BMS-779788 |
| Drug |
Oral Solution, Oral, 2 mg, Once daily, 7 days |
|
| BMS-779788 | Drug | Oral Solution, Oral, <= 4 mg, Once daily, 7 days |
|
| Placebo | Drug | Oral Solution, Oral, 0 mg, Once daily, 7 days |
|